Daré Bioscience, Inc.
DARE
$1.85
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 44,408.70% | 110.85% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 44,408.70% | 110.85% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 31,547.83% | 110.85% | |||
| SG&A Expenses | -36.90% | 5.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -32.10% | -3.47% | |||
| Operating Income | 59.93% | 4.07% | |||
| Income Before Tax | 59.53% | 11.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 59.53% | 11.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 59.53% | 11.30% | |||
| EBIT | 59.93% | 4.07% | |||
| EBITDA | 70.63% | 5.27% | |||
| EPS Basic | 63.87% | 38.32% | |||
| Normalized Basic EPS | 63.86% | 38.30% | |||
| EPS Diluted | 27.82% | 38.16% | |||
| Normalized Diluted EPS | 63.86% | 38.30% | |||
| Average Basic Shares Outstanding | 12.00% | 43.78% | |||
| Average Diluted Shares Outstanding | 12.00% | 43.78% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||